Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
21.3 EUR | +0.71% | +4.93% | -20.52% |
May. 15 | BASTIDE LE CONFORT MEDICAL : De facto maintained guidance; more disposals to propel debt reduction | |
May. 15 | Bastide: 8.2% increase in quarterly sales | CF |
Valuation
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 281.9 | 254 | 347 | 258 | 208.9 | 156.7 | - | - |
Enterprise Value (EV) 1 | 473.8 | 524.9 | 670.9 | 655.1 | 523.4 | 490 | 484.2 | 474.5 |
P/E ratio | 62.1 x | 22 x | 26 x | 19 x | 18.8 x | 9.26 x | 6.85 x | 5.97 x |
Yield | - | 0.78% | 0.57% | - | - | 2.22% | 2.72% | 3.07% |
Capitalization / Revenue | 0.84 x | 0.66 x | 0.78 x | 0.55 x | 0.41 x | 0.3 x | 0.28 x | 0.26 x |
EV / Revenue | 1.41 x | 1.37 x | 1.51 x | 1.4 x | 1.03 x | 0.93 x | 0.87 x | 0.8 x |
EV / EBITDA | 7.54 x | 6.45 x | 7.6 x | 6.9 x | 5.15 x | 4.61 x | 4.27 x | 3.91 x |
EV / FCF | 17.8 x | 69.6 x | 24.1 x | 183 x | 10.1 x | 18.8 x | 18 x | 14.9 x |
FCF Yield | 5.62% | 1.44% | 4.15% | 0.55% | 9.94% | 5.31% | 5.56% | 6.72% |
Price to Book | 4.44 x | 3.37 x | 4.29 x | 3.04 x | 2.43 x | 1.54 x | 1.3 x | 1.11 x |
Nbr of stocks (in thousands) | 7,321 | 7,321 | 7,306 | 7,309 | 7,303 | 7,408 | - | - |
Reference price 2 | 38.50 | 34.70 | 47.50 | 35.30 | 28.60 | 21.15 | 21.15 | 21.15 |
Announcement Date | 10/14/19 | 10/29/20 | 10/18/21 | 10/18/22 | 10/18/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 335.7 | 382.7 | 444.1 | 468.3 | 508 | 529 | 559.6 | 595.7 |
EBITDA 1 | 62.86 | 81.39 | 88.3 | 95 | 101.6 | 106.3 | 113.3 | 121.3 |
EBIT 1 | 28.42 | 32.76 | 36.98 | 38.9 | 42.79 | 44.3 | 48.8 | 52.63 |
Operating Margin | 8.46% | 8.56% | 8.33% | 8.31% | 8.42% | 8.37% | 8.72% | 8.84% |
Earnings before Tax (EBT) 1 | 11.58 | - | - | 21.02 | 22.77 | 18.5 | 30.2 | 36.3 |
Net income 1 | 5.091 | 11.6 | 13.45 | 13.68 | 12.05 | 16.83 | 22.73 | 26.03 |
Net margin | 1.52% | 3.03% | 3.03% | 2.92% | 2.37% | 3.18% | 4.06% | 4.37% |
EPS 2 | 0.6200 | 1.580 | 1.830 | 1.860 | 1.520 | 2.283 | 3.087 | 3.540 |
Free Cash Flow 1 | 26.65 | 7.538 | 27.85 | 3.586 | 52.05 | 26.03 | 26.9 | 31.87 |
FCF margin | 7.94% | 1.97% | 6.27% | 0.77% | 10.24% | 4.92% | 4.81% | 5.35% |
FCF Conversion (EBITDA) | 42.39% | 9.26% | 31.54% | 3.77% | 51.23% | 24.48% | 23.75% | 26.28% |
FCF Conversion (Net income) | 523.41% | 64.98% | 207.03% | 26.21% | 432.02% | 154.65% | 118.33% | 122.41% |
Dividend per Share 2 | - | 0.2700 | 0.2700 | - | - | 0.4700 | 0.5750 | 0.6500 |
Announcement Date | 10/14/19 | 10/29/20 | 10/18/21 | 10/18/22 | 10/18/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2022 Q2 | 2023 S1 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 206.1 | 221.7 | 114.9 | - | 127.9 | 258.3 | 127.9 | 137.1 | 265 |
EBITDA | - | - | - | - | - | - | - | - | - | - |
EBIT | - | 17.06 | 18.77 | - | 21.45 | - | 21.34 | - | - | - |
Operating Margin | - | 8.28% | 8.47% | - | - | - | 8.26% | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
Net income | 6.117 | - | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - |
EPS | 0.8400 | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/31/20 | 10/29/20 | 3/25/21 | 2/8/22 | - | 10/18/23 | 10/18/23 | 11/16/23 | 3/20/24 | 3/20/24 |
Balance Sheet Analysis
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 192 | 271 | 324 | 397 | 315 | 333 | 328 | 318 |
Net Cash position 1 | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 3.053 x | 3.328 x | 3.668 x | 4.18 x | 3.096 x | 3.135 x | 2.891 x | 2.621 x |
Free Cash Flow 1 | 26.6 | 7.54 | 27.9 | 3.59 | 52 | 26 | 26.9 | 31.9 |
ROE (net income / shareholders' equity) | 7.82% | 16.7% | 17.1% | 16.5% | 14% | 17.7% | 19.4% | 19% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | 8.660 | 10.30 | 11.10 | 11.60 | 11.80 | 13.80 | 16.20 | 19.00 |
Cash Flow per Share 2 | 6.980 | 10.40 | 11.40 | 12.50 | 11.50 | 11.00 | 12.20 | 13.20 |
Capex 1 | 34.4 | 39.8 | 46.5 | 53.3 | 53.6 | 53.4 | 56.1 | 58.4 |
Capex / Sales | 10.24% | 10.4% | 10.47% | 11.38% | 10.56% | 10.1% | 10.03% | 9.8% |
Announcement Date | 10/14/19 | 10/29/20 | 10/18/21 | 10/18/22 | 10/18/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.52% | 170M | |
+1.13% | 3.14B | |
0.00% | 1.96B | |
+19.18% | 1.79B | |
+66.09% | 695M | |
-13.53% | 449M | |
-45.62% | 309M | |
-15.65% | 134M | |
+3.85% | 67.96M |
- Stock Market
- Equities
- BLC Stock
- Financials Bastide Le Confort Médical